Lisanti Capital Growth LLC Takes $4.70 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Lisanti Capital Growth LLC acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 235,035 shares of the biotechnology company's stock, valued at approximately $4,698,000. Lisanti Capital Growth LLC owned 0.10% of ADMA Biologics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ADMA. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at $30,000. Quest Partners LLC acquired a new stake in ADMA Biologics in the 2nd quarter valued at about $29,000. EntryPoint Capital LLC bought a new position in shares of ADMA Biologics during the 1st quarter valued at about $31,000. USA Financial Formulas grew its stake in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after purchasing an additional 539 shares during the last quarter. Finally, CWM LLC raised its holdings in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Performance

ADMA Biologics stock traded down $0.14 during trading hours on Monday, hitting $22.48. The stock had a trading volume of 4,725,657 shares, compared to its average volume of 3,667,406. The company has a 50-day moving average of $18.12 and a two-hundred day moving average of $13.95. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a market cap of $5.24 billion, a PE ratio of 160.50 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the prior year, the firm earned ($0.02) EPS. The firm's quarterly revenue was up 78.4% compared to the same quarter last year. On average, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ADMA shares. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday. HC Wainwright upped their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th.

Insider Activity

In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now directly owns 449,088 shares in the company, valued at $7,589,587.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the firm's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the sale, the chief operating officer now owns 449,088 shares of the company's stock, valued at approximately $7,589,587.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.